JP2016041071A5 - - Google Patents

Download PDF

Info

Publication number
JP2016041071A5
JP2016041071A5 JP2015204285A JP2015204285A JP2016041071A5 JP 2016041071 A5 JP2016041071 A5 JP 2016041071A5 JP 2015204285 A JP2015204285 A JP 2015204285A JP 2015204285 A JP2015204285 A JP 2015204285A JP 2016041071 A5 JP2016041071 A5 JP 2016041071A5
Authority
JP
Japan
Prior art keywords
expression level
patient
beneficial response
gbp1
rna transcript
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015204285A
Other languages
English (en)
Japanese (ja)
Other versions
JP6190434B2 (ja
JP2016041071A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016041071A publication Critical patent/JP2016041071A/ja
Publication of JP2016041071A5 publication Critical patent/JP2016041071A5/ja
Application granted granted Critical
Publication of JP6190434B2 publication Critical patent/JP6190434B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2015204285A 2004-04-09 2015-10-16 化学療法剤に対する応答を予測するための遺伝子発現マーカー Expired - Lifetime JP6190434B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56103504P 2004-04-09 2004-04-09
US60/561,035 2004-04-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013103045A Division JP6130726B2 (ja) 2004-04-09 2013-05-15 化学療法剤に対する応答を予測するための遺伝子発現マーカー

Publications (3)

Publication Number Publication Date
JP2016041071A JP2016041071A (ja) 2016-03-31
JP2016041071A5 true JP2016041071A5 (https=) 2016-09-08
JP6190434B2 JP6190434B2 (ja) 2017-08-30

Family

ID=34981928

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007507495A Expired - Lifetime JP5813908B2 (ja) 2004-04-09 2005-04-07 化学療法剤に対する応答を予測するための遺伝子発現マーカー
JP2013103045A Expired - Lifetime JP6130726B2 (ja) 2004-04-09 2013-05-15 化学療法剤に対する応答を予測するための遺伝子発現マーカー
JP2015204285A Expired - Lifetime JP6190434B2 (ja) 2004-04-09 2015-10-16 化学療法剤に対する応答を予測するための遺伝子発現マーカー

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2007507495A Expired - Lifetime JP5813908B2 (ja) 2004-04-09 2005-04-07 化学療法剤に対する応答を予測するための遺伝子発現マーカー
JP2013103045A Expired - Lifetime JP6130726B2 (ja) 2004-04-09 2013-05-15 化学療法剤に対する応答を予測するための遺伝子発現マーカー

Country Status (9)

Country Link
US (2) US7871769B2 (https=)
EP (4) EP1737980A2 (https=)
JP (3) JP5813908B2 (https=)
AU (2) AU2005233593B2 (https=)
CA (2) CA2563074C (https=)
DK (1) DK2163650T3 (https=)
ES (2) ES2550614T3 (https=)
IL (4) IL178508A (https=)
WO (1) WO2005100606A2 (https=)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2992643C (en) * 2002-03-13 2019-06-18 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
ES2609234T3 (es) 2003-06-24 2017-04-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP1756308A1 (en) * 2004-04-23 2007-02-28 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
EP1815014B1 (en) * 2004-11-05 2012-03-21 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
JP5020088B2 (ja) * 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
SG156625A1 (en) * 2004-12-08 2009-11-26 Aventis Pharma Inc Method for measuring resistance or sensitivity to docetaxel
WO2007013946A2 (en) * 2005-07-20 2007-02-01 University Of South Florida Method of predicting responsiveness to chemotherapy and selecting treatments
EP1937837A2 (en) * 2005-07-29 2008-07-02 Siemens Healthcare Diagnostics Inc. Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
CN101365806B (zh) * 2005-12-01 2016-11-16 医学预后研究所 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US7892740B2 (en) 2006-01-19 2011-02-22 The University Of Chicago Prognosis and therapy predictive markers and methods of use
WO2007085497A2 (en) * 2006-01-30 2007-08-02 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
JP2008017832A (ja) * 2006-06-13 2008-01-31 Sysmex Corp がんの転移の判定方法及び判定装置
US20080076134A1 (en) * 2006-09-21 2008-03-27 Nuclea Biomarkers, Llc Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US20110178154A1 (en) * 2007-02-06 2011-07-21 Birrer Michael J gene expression profile that predicts ovarian cancer subject response to chemotherapy
JP5832721B2 (ja) * 2007-03-14 2015-12-16 バイオンシル・エス．アール．エル．Ｂｉｏｎｓｉｌ Ｓ．Ｒ．Ｌ． 上皮腫瘍細胞における薬剤耐性のモジュレータ化合物
US20090258795A1 (en) * 2007-03-15 2009-10-15 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
EP1978106A1 (en) * 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
EP2191020A2 (en) * 2007-08-16 2010-06-02 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
JP2009050189A (ja) * 2007-08-24 2009-03-12 Sumitomo Bakelite Co Ltd 抗癌剤の有効性予測方法
AU2008298560A1 (en) * 2007-09-14 2009-03-19 Ventana Medical Systems, Inc. Prostate cancer biomarkers
JP5303132B2 (ja) * 2007-09-20 2013-10-02 シスメックス株式会社 がん細胞の存否を判定する方法及び装置
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
MX2010005080A (es) 2007-11-07 2010-07-28 Genentech Inc Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40.
US8168755B2 (en) * 2008-05-07 2012-05-01 Eutropics Pharmaceuticals, Inc. Antibodies specific to heterodimers of Bcl-2 family and uses thereof
DK2568053T3 (da) * 2008-05-12 2014-07-21 Genomic Health Inc Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder
EP2806054A1 (en) * 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
DK2297359T3 (en) 2008-05-30 2014-02-24 Univ Utah Res Found Gene expression profiles to predict the outcome of breast cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
US9670546B2 (en) 2008-07-15 2017-06-06 Epigenomics Ag Methods and nucleic acids for analyses of cell proliferative disorders
KR100996994B1 (ko) * 2008-08-18 2010-11-25 울산대학교 산학협력단 간세포암종 수술후 재발 또는 재발 발병 위험성의 진단방법
US20110262453A1 (en) * 2008-08-20 2011-10-27 Witta Samir E Markers for Assessing the Susceptibility of Cancer to IGF-1R Treatment
JP2010057486A (ja) * 2008-09-02 2010-03-18 Sysmex Corp 化学療法に対するがん患者の応答の予測方法
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
US20130324478A1 (en) * 2008-09-08 2013-12-05 Laurence Faure Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
CN102232117A (zh) * 2008-10-14 2011-11-02 卡里斯Mpi公司 描绘肿瘤类型生物标志模式和特征集的基因靶和基因表达的蛋白靶
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
GB2463401B (en) 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
EP2373809A1 (en) * 2008-12-10 2011-10-12 Ipsogen Methods for identifying erbb2 alteration in tumors
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
CA2751688A1 (en) * 2009-02-06 2010-08-12 Biao He Emx2 in cancer diagnosis and prognosis
US8972899B2 (en) 2009-02-10 2015-03-03 Ayasdi, Inc. Systems and methods for visualization of data analysis
KR101787768B1 (ko) * 2009-04-18 2017-10-18 제넨테크, 인크. 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
EP3178944B1 (en) 2010-01-11 2019-05-15 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
CA2800557A1 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
EP2588864A1 (en) * 2010-07-02 2013-05-08 Topogen Inc. Method for diagnosis of bladder cancer and related kits
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
TW201209163A (en) * 2010-07-12 2012-03-01 Opko Curna Llc Treatment of BCL2 binding component 3 (BBC3) related diseases by inhibition of natural antisense transcript to BBC3
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
SG187045A1 (en) 2010-08-13 2013-02-28 Somalogic Inc Pancreatic cancer biomarkers and uses thereof
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
PT2619576T (pt) 2010-09-24 2020-09-14 Niels Grabe Meios e métodos para a previsão de resposta ao tratamento de um paciente com cancro
RU2565550C2 (ru) 2010-09-24 2015-10-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Прямой захват, амплификация и секвенирование днк-мишени с использованием иммобилизированных праймеров
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
JP5828446B2 (ja) * 2011-02-10 2015-12-09 国立大学法人秋田大学 扁平上皮癌組織の放射線感受性マーカー
CA2742342A1 (en) * 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
WO2012153187A2 (en) * 2011-05-06 2012-11-15 Xentech Markers for cancer prognosis and therapy and methods of use
BR112013031019A2 (pt) * 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
WO2012174203A2 (en) * 2011-06-14 2012-12-20 Anthony Albino Methods and kits for the detection and treatment of recurring prostate cancer
WO2013050998A1 (en) * 2011-10-04 2013-04-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cd247 as a biomarker for assessing the effect of chemotherapeutic and biological drugs
WO2013055704A1 (en) * 2011-10-10 2013-04-18 Ayasdi, Inc. Systems and methods for mapping new patient information to historic outcomes for treatment assistance
AU2012345789B2 (en) * 2011-11-30 2018-02-15 British Columbia Cancer Agency Branch Methods of treating breast cancer with taxane therapy
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US10519506B2 (en) 2011-12-22 2019-12-31 Baylor Research Institute Identification of metastasis-specific miRNA and hypomethylation signatures in human colorectal cancer
WO2013109690A1 (en) * 2012-01-17 2013-07-25 Myriad Genetics, Inc. Breast cancer prognosis signatures
US8725426B2 (en) 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
FR2987446B1 (fr) * 2012-02-28 2016-01-01 Univ Nice Sophia Antipolis Test diagnostic de la resistance a l'azacitidine
WO2013170174A1 (en) * 2012-05-10 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of diagnosing, treating and determining progression and survival of cancer cells using bcl-2 antagonist of cell death (bad) pathway gene signature
US20150150869A1 (en) 2012-06-20 2015-06-04 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
DK3435084T3 (da) 2012-08-16 2023-05-30 Mayo Found Medical Education & Res Prostatakræftprognose under anvendelse af biomarkører
WO2014078700A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
WO2014085653A1 (en) * 2012-11-30 2014-06-05 Celera Corporation Multi-gene signatures for predicting response to chemotherapy or risk of metastasis for breast cancer
MX2015006955A (es) 2012-12-03 2016-01-25 Almac Diagnostics Ltd Prueba de diagnostico molecular para cancer.
WO2014121177A1 (en) * 2013-02-01 2014-08-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Biomarkers and methods for predicting benefit of adjuvant chemotherapy
EP2971101A2 (en) * 2013-03-15 2016-01-20 Janssen Pharmaceutica N.V. Assay for predictive biomarkers
JP2016521979A (ja) 2013-05-30 2016-07-28 ジェノミック ヘルス， インコーポレイテッド 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
WO2015017788A1 (en) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
WO2015066305A1 (en) 2013-10-30 2015-05-07 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
US20170184602A1 (en) * 2014-04-24 2017-06-29 Pfizer Inc. Cancer treatment
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
CN104004844A (zh) * 2014-05-28 2014-08-27 杭州美中疾病基因研究院有限公司 乳腺癌21基因联合检测试剂盒及其制备方法
ES2792227T3 (es) 2014-09-26 2020-11-10 Somalogic Inc Predicción de evento de riesgo cardiovascular y usos de la misma
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
JP7065610B6 (ja) * 2014-10-24 2022-06-06 コーニンクレッカ フィリップス エヌ ヴェ 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測
AU2015334841B2 (en) * 2014-10-24 2022-02-03 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
US10793915B2 (en) 2015-01-12 2020-10-06 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
CN107548498A (zh) 2015-01-20 2018-01-05 南托米克斯有限责任公司 用于反应预测高级别膀胱癌中的化疗的系统和方法
CN108291227A (zh) 2015-10-14 2018-07-17 拜奥-帕斯控股股份有限公司 用于脂质体制剂的对乙氧基核酸
WO2017096458A1 (en) * 2015-12-07 2017-06-15 Ontario Institute For Cancer Research (Oicr) Immune gene signature predictive of anthracycline benefit
WO2017100732A1 (en) * 2015-12-10 2017-06-15 Nantomics, Llc Integrated analysis to determine prognosis after treatment for primary breast cancer
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
AU2017325971A1 (en) 2016-09-16 2019-04-11 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
EP3571322B9 (en) 2017-01-20 2023-10-04 VERACYTE SD, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
EP3593140A4 (en) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. SUBTYPING PROSTATE CANCER TO PREDICT RESPONSE TO HORMONE THERAPY
WO2018165532A1 (en) 2017-03-10 2018-09-13 Baylor Research Institute Methods for diagnosing and treating gastric cancer using mirna expression
EA201992485A1 (ru) 2017-04-19 2020-02-17 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования stat3
EA201992490A1 (ru) 2017-04-19 2020-03-03 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования bcl2
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
RU2675236C1 (ru) * 2018-02-22 2018-12-18 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования развития метастазов у больных раком молочной железы
US12174192B2 (en) * 2018-07-12 2024-12-24 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
WO2021047992A1 (en) * 2019-09-09 2021-03-18 Oaklabs Gmbh Superior biomarker signature to predict the response of a breast cancer patient to chemotherapy
CN111184865B (zh) * 2020-03-09 2021-11-16 复旦大学附属金山医院 Stat1在耐紫杉醇上皮性卵巢癌治疗中的用途
GB202116745D0 (en) * 2021-11-19 2022-01-05 Institute Of Cancer Res Royal Cancer Hospital Prognostic and treatment response predictive method
EP4623092A1 (en) * 2022-11-21 2025-10-01 Merck Sharp & Dohme LLC Genome wide tumor derived gene expression based signatures associated with poor prognosis for melanoma patients with early stage disease
WO2025171441A1 (en) * 2024-02-13 2025-08-21 The Council Of The Queensland Institute Of Medical Research Prognostic signature for cancer recurrence and responsiveness

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35491E (en) 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
CA1252046A (en) 1982-11-04 1989-04-04 Martin J. Cline Methods for oncogenic detection
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5858678A (en) 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
EP1655369A1 (en) 1995-12-18 2006-05-10 Sugen, Inc. Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
US5670325A (en) 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US5928870A (en) 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6146828A (en) 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6143529A (en) 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6020137A (en) 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6100029A (en) 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US5861278A (en) 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
US6245523B1 (en) 1996-11-20 2001-06-12 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US5830665A (en) 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
WO1999002714A1 (en) 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
GB2339200B (en) 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
US6696558B2 (en) 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
US6331396B1 (en) 1998-09-23 2001-12-18 The Cleveland Clinic Foundation Arrays for identifying agents which mimic or inhibit the activity of interferons
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
AU3246200A (en) 1999-02-25 2000-09-14 Boris Bilynsky Nucleic acid molecules associated with melanoma and thyroid tumors
US20020039764A1 (en) 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
DE19922052A1 (de) * 1999-05-14 2000-11-16 Theragen Molekularmedizinische Verfahren zum Nachweis der Wirkung von unterschiedlichen Chemotherapeutika und/oder einer Strahlentherapie bei malignen Erkrankungen sowie Verfahren zur Auswahl wirkungsvoller therapeutischer Mittel zu deren Therapie
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6710170B2 (en) 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
CA2391805A1 (en) 1999-10-06 2001-04-12 The Regents Of The University Of California Differentially expressed genes associated with her-2/neu overexpression
EP1672070A3 (en) 1999-12-01 2006-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6750013B2 (en) 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
EP1276901A2 (en) 2000-01-13 2003-01-22 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
US6618679B2 (en) 2000-01-28 2003-09-09 Althea Technologies, Inc. Methods for analysis of gene expression
CA2395872A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030165831A1 (en) 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US7157227B2 (en) 2000-03-31 2007-01-02 University Of Louisville Research Foundation Microarrays to screen regulatory genes
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2002008461A2 (en) 2000-07-21 2002-01-31 Global Genomics Ab A METHOD AND AN ALGORITHM FOR mRNA EXPRESSION ANALYSIS
AU2001277172A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-trans protein and related reagents and methods of use thereof
AU2001277202A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
WO2002008260A2 (en) 2000-07-26 2002-01-31 Stanford University Bstp-ecg1 protein and related reagents and methods of use thereof
WO2002010436A2 (en) 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
AU2002214576A1 (en) 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US20030143539A1 (en) * 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7097966B2 (en) 2001-01-12 2006-08-29 Yale University Detection of survivin in the biological fluids of cancer patients
US7776518B2 (en) 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
JP2005503760A (ja) 2001-01-24 2005-02-10 プロテイン デザイン ラブス， インコーポレイテッド 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
US7756643B2 (en) * 2001-03-01 2010-07-13 Epigenomics Ag Method for determining the biological effect and/or activity of at least one drug, chemical substances and/or pharmaceutical composition based on their effect on the methylation status of DNA
NZ528205A (en) 2001-03-12 2006-09-29 Monogen Inc Cell-based detection and differentiation of disease status in a cytological sample using a panel comprising a plurality of probes
US20030077582A1 (en) * 2001-03-27 2003-04-24 Wen-Lin Kuo Methods for diagnosing and monitoring malignancies by screeining gene copy numbers
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
JP2005500832A (ja) 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド 乳癌患者の診断および予後
US7125680B2 (en) 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
US20040009489A1 (en) 2001-09-28 2004-01-15 Golub Todd R. Classification of lung carcinomas using gene expression analysis
CN1612936A (zh) 2001-11-09 2005-05-04 苏尔斯精细医药公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US20030124130A1 (en) * 2002-01-02 2003-07-03 Brown Robert E. Proteomic analysis of tumors for development of consultative report of therapeutic options
JP2005532036A (ja) * 2002-01-09 2005-10-27 理化学研究所 癌プロフィール
US7704700B2 (en) * 2002-02-12 2010-04-27 Burnham Institute For Medical Research Methods for determining the prognosis for patients with a prostate neoplastic condition using inhibitor of apoptosis polypeptides
CA2992643C (en) 2002-03-13 2019-06-18 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
EP1492871A2 (en) 2002-03-28 2005-01-05 QLT Inc. Cancer associated protein kinases and their uses
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
EP1365034A3 (en) 2002-05-21 2004-02-18 Bayer HealthCare AG Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2516553C (en) 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
WO2004111603A2 (en) 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
ES2609234T3 (es) 2003-06-24 2017-04-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
WO2005015236A2 (en) 2003-07-18 2005-02-17 Roche Diagnostics Gmbh A method for predicting the progression of adenocarcinoma
EP1522594A3 (en) 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP2383350B1 (en) 2004-05-07 2018-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
CA2569202A1 (en) * 2004-05-28 2005-12-15 Board Of Regents, The University Of Texas System Multigene predictors of response to chemotherapy
JP5020088B2 (ja) 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
EP1815014B1 (en) 2004-11-05 2012-03-21 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
CA2611728A1 (en) 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
NZ544432A (en) 2005-12-23 2009-07-31 Pacific Edge Biotechnology Ltd Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS
NZ593226A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
US20090258795A1 (en) 2007-03-15 2009-10-15 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
EP2191020A2 (en) 2007-08-16 2010-06-02 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
WO2009114836A1 (en) 2008-03-14 2009-09-17 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
DK2568053T3 (da) 2008-05-12 2014-07-21 Genomic Health Inc Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder
WO2010056931A1 (en) 2008-11-14 2010-05-20 Intelligent Oncotherapeutics, Inc. Methods for identification of tumor phenotype and treatment
CA2745961A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
SG10201401722XA (en) 2009-05-01 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy
CA3043089A1 (en) 2009-11-23 2011-05-26 Genomic Health, Inc. Methods to predict clinical outcome of cancer

Similar Documents

Publication Publication Date Title
JP2016041071A5 (https=)
Khan et al. MicroRNA biogenesis, gene silencing mechanisms and role in breast, ovarian and prostate cancer
Nassar et al. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction
Kachalaki et al. Cancer chemoresistance; biochemical and molecular aspects: a brief overview
Samandari et al. Liquid biopsies for management of pancreatic cancer
JP2016174600A5 (https=)
JP2017055769A5 (https=)
Hoppe et al. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment
BR112012024718A2 (pt) método para a predição da recorrência de câncer da mama sob tratamento endócrino
JP2007507222A5 (https=)
JP2010538609A5 (https=)
WO2016172710A3 (en) Methods and reagents for determination and treatment of organotropic metastasis
WO2016036994A8 (en) Method of analysis allowing avoidance of surgery
WO2013098797A3 (en) Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
RU2017125053A (ru) Терапевтические, диагностические и прогностические способы для рака мочевого пузыря
WO2019075251A3 (en) Cancer score for assessment and response prediction from biological fluids
HK1213946A1 (zh) 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法
JP2016521979A5 (https=)
WO2016203262A3 (en) Gene signatures predictive of metastatic disease
Su et al. Antrodia cinnamomea sensitizes radio-/chemo-therapy of cancer stem-like cells by modulating microRNA expression
JP2017536085A5 (https=)
Nikolova et al. 52P MiRNA profile associated with the invasiveness in non-functioning pituitary adenomas
Wang et al. The Long Noncoding RNA SPRY4-IT1 Contributes to proliferation of Human breast cancer Cells via upregualtion of ZNF703 Expression
Dai et al. Machine learning models for predicting lymph node and distant metastases in colorectal cancer
Albain et al. Proceedings of the first global workshop on breast cancer: Pathways to the evaluation and clinical development of novel agents for breast cancer